On 2026年5月10日，the U.S. Food and Drug Administration （FDA） officially updated the 510(k) Premarket Notification Guidance Document，clearly requiring that medical sensor products containing wireless communication，remote configuration，or firmware upgrade functions simultaneously provide a cybersecurity verification report issued by an ISO/IEC 17025 accredited laboratory when submitting a 510(k) application。This policy directly affects Chinese medical sensor companies exporting to the United States，such as those producing continuous glucose monitoring （CGM） devices and implantable pressure sensors。Due to the tight compliance preparation timeline （requiring at least 12 weeks），it has become a key development that must be prioritized in the current field of cross-border medical device compliance。

Event Overview

On 2026年5月10日，the U.S. FDA issued the revised 510(k) Premarket Notification Guidance Document，adding mandatory cybersecurity verification requirements：all medical sensors with wireless communication，remote configuration，or firmware upgrade capabilities must submit，together with their 510(k) application materials，a cybersecurity verification report issued by an ISO/IEC 17025 accredited laboratory。The report must cover three core indicators——CVE vulnerability scanning results，firmware digital signature integrity verification，and the effectiveness of the OTA （over-the-air） upgrade rollback protection mechanism。The new regulation will officially take effect from 2026年8月1日。

Which Segmented Industries Will Be Affected

Direct trading enterprises：mainly refers to companies exporting medical sensors to the U.S. market under their own brands or in ODM/OEM models。Although the 510(k) applicant is usually a U.S. agent or certificate holder，the technical documents and verification data must be provided by the manufacturer，so they need to directly assume responsibility for organizing cybersecurity verification，submitting samples for testing，and integrating documentation；the impact is reflected in longer application cycles，higher verification costs，and the need to add dedicated cybersecurity sections to the technical documentation system。

Contract manufacturing enterprises：specifically refers to manufacturers undertaking outsourced production of products such as CGM and implantable pressure sensors。The new regulation does not exempt contract manufacturers from responsibility——if they participate in firmware development，hardware design，or security configuration steps in the production process，they must cooperate in providing design inputs，security architecture descriptions，and verifiable firmware build environment records；the impact is mainly reflected in the need for production lines to retain auditable firmware signing procedures，OTA upgrade logs，and version control evidence chains。

Supply chain service enterprises：including third-party service providers that offer cybersecurity testing，ISO/IEC 17025 laboratory coordination，FDA registration agency services，and other support for medical sensor companies。Their service content will expand from conventional EMC/electrical safety to new dimensions such as CVE scanning toolchain deployment，signing key management consulting，and rollback mechanism verification scheme design；the impact lies in the need for service standards to align with the FDA's latest verification indicators，as well as the capability to explain the technical connotations of the three core indicators to customers。

What Key Points Should Relevant Enterprises or Practitioners Pay Attention To，and How Should They Respond at Present

Pay attention to follow-up official statements or policy changes

The FDA has not yet announced the specific template for the verification report，the list of accepted CVE scanning tools，or the minimum technical threshold for rollback protection。What is currently more worth attention is the online technical Q&A session that the FDA will hold in mid-June 2026，as well as possible supporting FAQ updates that may be released in the “Digital Health Center of Excellence” section of its official website。

Pay attention to changes in key product categories，key markets，or key business links

Continuous glucose monitoring （CGM） devices are generally classified as high-risk because they commonly use Bluetooth transmission + cloud synchronization + APP remote calibration，and are expected to become one of the first key review targets；products that have already obtained 510(k) clearance but have not yet completed their first market launch must also submit the verification report if they plan to enter the U.S. market for the first time after 2026年8月1日——the exemption clause of “continuation of previous clearance” does not apply。

Distinguish between policy signals and actual business implementation

This guidance belongs to a mandatory Guidance Document，not a Regulation，but the FDA has already treated it as a substantive market entry threshold in review practice。Analysis shows：within 6 months after the release of similar guidance in the past （such as the 2022 premarket cybersecurity guidance），about 73% of Additional Information （AI） deficiency letters involved missing cybersecurity documentation，so the practical binding force of this update is close to regulatory requirements。

Prepare procurement，supply chain，communication，or contingency plans in advance

It is recommended that enterprises immediately review whether their existing product firmware signing mechanisms support FIPS 140-2 Level 1 or above key storage；confirm whether OTA upgrade packages have a dual mechanism of hash verification + signature verification；and initiate pre-communication with cybersecurity laboratories already qualified with ISO/IEC 17025 to reserve testing slots in advance——because the current average queue cycle of globally qualified laboratories has reached 8–10 weeks。

Editorial Viewpoint / Industry Observation

Observably，this guidance update is not an isolated move，but a refined implementation of the FDA's Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions （2023 edition），marking that cybersecurity verification is shifting from “recommended submission” to “mandatory submission”。At present，it is more like a clear regulatory signal rather than a completed compliance endpoint：on the one hand，the three core indicators （CVE scanning，signature integrity，and OTA rollback protection） have not yet defined quantified qualification standards；on the other hand，the FDA has not yet clarified retroactive requirements for products already on the market。What the industry needs to continue paying attention to is its potential linkage with the U.S. Cybersecurity Labeling Program——the latter may affect end-user procurement decisions，thereby pushing upstream verification toward normalization。

Conclusion
The essence of this FDA 510(k) guidance update is to move cybersecurity verification for medical sensors from the quality system stage forward to the market access stage，highlighting the evolution of regulatory logic from “post-event supervision” to “pre-event verification”。For Chinese exporters，this does not merely involve a one-time test，but requires the establishment of sustainable Secure Software Development Lifecycle （S-SDLC） capabilities。At present，it is more appropriate to understand it as：a compliance critical point with a strong enforcement orientation，whose significance lies not in breakthroughs in technical difficulty，but in driving enterprises to transform cybersecurity from an add-on item into an inherent attribute of product definition。

Information source description
Main source：the 510(k) Premarket Notification Guidance Document published on the official FDA website （revised version，publication date：2026年5月10日）
Items requiring continued observation：whether the FDA will issue supplementary explanations on the coverage scope of CVE scanning，the recommended list of firmware signing algorithms，and the methodology for OTA rollback protection verification；and whether the list of recognized qualifications for third-party laboratories will be dynamically updated。